Karsten Krug
Director, Head of Bioinformatics Frontier Medicines
Karsten Krug has had an extensive work experience in the field of bioinformatics and computational science. Karsten is currently employed as the Associate Director and Head of Bioinformatics at Frontier Medicines since December 2022.
Before joining Frontier Medicines, Krug worked at the Broad Institute of MIT and Harvard for several years. Karsten started as a Research Assistant at Leipzig University in 2008. Karsten then moved on to work as a PhD student at the Proteome Center Tuebingen from January 2009 to July 2013, where his research focused on high accuracy mass spectrometry in the refinement of genome annotation.
Seminars
Thursday 5th February 2026
Leveraging the Unique Power of Chemoproteomics for Hit Identification & Screening to Transform Discovery of Therapeutic Candidates
9:00 am
- Explore the Frontier Platform which combines chemoproteomics, covalent fragment-based discovery, and AI to access more than 90% of the proteome
- Discover how a custom-built covalent fragment library that leverages the concept of enantiomer pairs was used to reveal immediate SAR through enantiomer-specific hits, enabled by chemoproteomic screening in live cells capturing proteome-wide engagement signatures
- Presenting novel quality-control metrics for large-scale chemoproteomic screening of covalent enantiomer libraries, complementing compound purity checks and improving triage of true hits for downstream assays
